tbuckley/cabot-search huggingface dataset:
AB0505 Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus
Authors: R. Dhahri, I. Gharsallah, N. Boussetta, S. Sayhi, L. Metoui, F. Laajili
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pulmonary arterial hypertension (PAH) is a rare disease characterized by the progressive increase in pulmonary artery pressures, leading to right heart failure. Systemic lupus erythematosus (SLE) is the second connectivity after Scleroderma can be complicated by PAH. This study aims to estimate the prevalence of PAH in SLE, detected by echocardiography. <h3>Methods</h3> This is a retrospective study of ten years about 80 patients with SLE fulfilling the criteria of the ACR (American College of Rheumatology), followed in our department of internal medicine. Echocardiography with measurement of pulmonary artery pressure was performed in 72 patients. Above 30 mmHg mean arterial pressure was used to define PAH. <h3>Results</h3> Ten patients (7% of cases) had pulmonary arterial pressure greater than 30mmHg. Two of them had lung disease (the first with emphysematous lung and the other a lupus interstitial lung disease). Three patients had mitral insufficiency. A syndrome of anti-phospholipid antibodies (APS) was noted in four patients (40% of cases). Five other lupus patients had isolated PAH (50% of cases). We noted a positive anti-Sm antibody in three patients (40% of cases). <h3>Conclusions</h3> PAH is a rare and severe complication of SLE and is a bad prognostic factor. Its detection is based on echocardiography. PAH lupus may be the expression of APS or secondary to pulmonary fibrosis or left valvulopathy. The treatment is based on corticosteroids and immunosuppressive association. Anticoagulants are indicated in cases of APS. Due to the severity of PAH in SLE, a screening echocardiography should be systematically offered to patients with SLE to treat early this serious complication and to enhance prognosis. <h3>Disclosure of Interest</h3> None declared
Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL).
Authors: Maria Alma Rodriguez, Anna Ter Veer, Auayporn Nademanee, Joyce Niland, Eva Lepisto, Michelle Kho, Ann LaCasce, Jane Carrie Weeks, Myron Czuczman, Michael Millenson, Jonathan Friedberg, Andrew D. Zelenetz
Journal: Blood (2006)
OC-060 An Observational Prospective Clinical Audit to Determine the Presence of Alcohol-Related Brain Injury (ARBI) in Patients Presenting to Acute Care
Authors: L Owens, L Chinnappan, A Thompson, C Kullu, P Richardson, K Mannix
Journal: Gut (2016)

<h3>Introduction</h3> Alcohol dependence is a relapsing condition resulting in significant comorbidity and subsequent use of health resources. Patients are repeatedly admitted into acute care for acute alcohol withdrawal management and stabilisation of their physical condition. Patients are frequently labelled as treatment resistant/non-compliant, despite the fact that a significant proportion of these individuals may have underlying alcohol-related brain injury (ARBI), which results in reduced capacity to understand or engage in treatment.<sup>1</sup> Unfortunately, it is rare that assessment for ARBI is undertaken, and therefore the condition goes undetected. <h3>Methods</h3> Patients presenting to acute care with an alcohol-related problem were assessed for risk of ARBI by the Alcohol Specialist Nurse performing a <b>MoCA<sup>©</sup></b>.<sup>2</sup> A score of &lt;26 triggered a referral to a dedicated ARBI clinic delivered by a liaison psychiatrist. The aims of this study were to a) explore the scale of the problem, b) describe the complexity of the patient group c) provide evidence for the need and development of bespoke, integrated care pathways. <h3>Results</h3> Eighty-nine patients were diagnosed as having ARBI (MoCA &lt; 26) in 12 months 35 female; 57 male, with a mean age of 54 yrs (SD = 10). These patients had average of 9 hospital admissions in 5 years (range 1 to 48). Patients primary reason for admission was; 31 (46%) ALD/Cirrhosis, 21 (23%) alcohol excess (o) 13 (15%) seizure, 6 (7%) ARBI, 2 (1%) stroke and 6 (7%) other. In the previous 5 years; 50 (56%) patients had a fracture, 10 had multiple fractures and 20 had &gt;2 grand mall seizures. Median alcohol consumption was 24 units per day (IQR = 15) at baseline and showed no statistical difference at 3 or 6 month follow-up. <h3>Conclusion</h3> Screening for ARBI results in detection of otherwise undiagnosed cognitive impairment that renders traditional alcohol treatment approaches ineffective. This group of patients have significant co-morbid conditions likely to benefit from integrated bespoke pathways of care. An acute admission should be utilised as an ideal window of opportunity to assess the patient while they are alcohol free, and plan appropriate treatment which has the potential to prevent people progressing to end stage dementia. <h3>References</h3> 1 Wilson K. Alcohol and brain damage in adults with reference to high-risk groups. <i>Royal College of Psychiatrists</i>. Report number: CR185, 2014. 2 Wester AJ, Westhoff J, Kessels RPC, <i>et al</i>. The Montreal Cognitive Assessment (MoCA) as a measure of severity of amnesia in patients with alcohol-related cognitive impairments and Korsakoff Syndrome. <i>Clinical Neuropsychiatry</i>. 2013;<b>10</b>:131141. <h3>Disclosure of Interest</h3> None Declared
Sixty seconds on . . . TrialsTracker
Authors: Gareth Iacobucci
Journal: BMJ (2016)

Guess again. It’s actually a new automated tracking service to monitor clinical trials. More specifically, it aims to shine a light on the drug companies and universities that aren’t publishing their trial results.

Pretty damning, overall. The tracker (trialstracker.ebmdatalab.net), developed by academics from Oxford University and some of the key players in the AllTrials campaign (www.alltrials.net), found that 45% of all trials …
THU0584 Clinical Characteristics of Sarcoid Arthropathy
Authors: S. Kobak, F. Sever, O. Usluer, T. Goksel, M. Orman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Sarcoidosis is known as a Th1-mediated disease which can mimic many primary rheumatologic diseases or can sometimes co-exist with them. Clinical characteristics of sarcoid arthropathy are not well described as only referral-based studies have been reported. <h3>Objectives</h3> The aim of this study were to evaluate the incidence and clinical characteristics of sarcoid arthropathy. <h3>Methods</h3> We used an inception cohort of sarcoidosis patients seen between July 2011 and August 2015. A total of 114 (32 male) sarcoidosis patients, who admitted to our clinic were included in the study. Clinical, demographical, laboratory, radiological and histological data of these patients obtained during 4-year follow-up and treatment period were compiled and analyzed. <h3>Results</h3> The mean patient age was 48.1 years (20–82 years), and the mean disease duration was 40.5 months (1–300 months). Sarcoid arthritis was observed in 71 (62.3%), and arthralgia in 106 (92.9%) patients. Out of the 71 patients with arthritis, 61 (85.9%) had involvement of ankle, 7 (9.8%) knee, two (2.8%) wrist, MCP and PIP joints, and one (1.4%) had shoulder periarthritis. Oligoarthritis (two to four joints) was the most common pattern followed by monoarthritis and polyarthritis. When the correlation between clinical findings were considered, erythema nodosum and arthritis and female gender were found to be correlated (p=0.03, p=0.001, respectively). Again in patients with arthritis, even higher levels of CRP/ESR as well as ANA and RF positivity were observed (p=0.03, p=0.01, p=0.01 and p=0.02, respectively). Eleven patients had another rheumatic pathology concurrent with sarcoidosis (1SjS, 3RA, 1Still disease, 1 Scleroderma, 4AS, 1FMF). <h3>Conclusions</h3> Inflammatory arthritis occurs in a majority of patients with sarcoidosis. Acute arthritis with bilateral ankles involvement was the most common pattern of sarcoid arthropathy. Sarcoidosis can mimic many primary rheumatic disease and/or may coexist. Sarcoidosis should be considered not only as a mimicker but also as a Th1-mediated primary rheumatologic pathology. <h3>Disclosure of Interest</h3> None declared
A Study on the Prognosis of Patients Relapsing after Autologous Stem Cell Transplantation (auto-SCT) for Follicular Lymphoma (FL): The Impact of Remission Duration.
Authors: Julia Stumm, Jens Dreyhaupt, Martin Kornacker, Manfred Hensel, Michael Kneba, Anthony D.Ho, Norbert Schmitz, Peter Dreger
Journal: Blood (2006)
Growth Factor Independent-1 (Gfi1) As a New Target for Human Leukemia Therapy
Authors: Cyrus Khandanpour, James D. Phelan, Riyan Chen, Shane Horman, Lothar Vassen, Marie-Claude Gaudreau, Joseph Krongold, Jinfang Zhu, William E Paul, Judith Schütte, Berthold Goettgens, Ulrich Duehrsen, H. Leighton Grimes, Tarik Moroy
Journal: Blood (2011)
Construction of An Outpatient Erythrocytapheresis Program for Pediatric Patients with Sickle Cell Disease
Authors: Paulette Bryant, Richard Parmley, Christine Bolen, Theresa Sunderland, Robert Johnson, Jennifer Weisner, Karen Nishioka, Karen Roberts, Richard Towell, Jodi P. Strong, Evelyn Lockhart, Mark Mogul
Journal: Blood (2008)
Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy
Authors: Marina Caskey, Florian Klein, Michel C. Nussenzweig
Journal: New England Journal of Medicine (2016)

High serum titers of neutralizing antibodies develop in a small fraction of people who become infected with HIV-1. Isolation of such broadly neutralizing antibodies (bNAbs) has led to a new and promising approach to combat HIV-1 infection.
Lethality of Mouse Tissue Factor Pathway Inhibitor Gene Disruption Is Rescued By Transgenic Human Tissue Factor Pathway Inhibitor Knock in
Authors: Robert Pachlinger, Rudolf Hartmann, Andrea Kolm, Erwin Panholzer, Nadja Ullrich, Fabian Knofl, Maria Schuster, Werner Hoellriegl, Friedrich Scheiflinger, Michael Dockal
Journal: Blood (2015)
Clinicopathological and Prognostic Characteristics of CD33-Positive Multiple Myeloma.
Authors: Naohi Sahara, Kazunori Ohnishi, Takaaki Ono, Yuya Sugimoto, Miki Kobaysahi, Kaori Takeshita, Kazuyuki Shigeno, Satoki Nakamura, Kensuke Naito, Akihiro Takeshita, Ryuzo Ohno
Journal: Blood (2005)
Focal Deletion of Genes Involved in the Control of Cell Cycle Progression Contributes to Growth Factor Independence in Acute Lymphoblastic Leukemia Cells
Authors: Bart Nijmeijer, Karoly Szuhai, Henriette M Goselink, Marianke LJ Van Schie, Danielle De Jong, Roelof Willemze, J.H. Frederik Falkenburg
Journal: Blood (2008)
Impact of Rituximab on Peripheral Blood Stem Cell Mobilization and Collection Following ACVBP Regimen in Poor Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Large Cohort of Patients from Two Prospective GELA Trials.
Authors: Francois Lefrere, Dominique bastit-Barrau, Suzanne Mathieu, Alain Bohbot, Philippe Bourrin, Gilles Andre Salles, Herve Tilly, Nicolas Mounier, Olivier Fitoussi, Corinne Haioun
Journal: Blood (2008)
A Comparison of Human CMVpp65-Specific Central Memory and Effector Memory CD8 T-Cells When Stimulated in-Vivo with IL-2 or IL-15/IL-15Rα Complex in a Murine Xenograft Model of Adoptive Cell Therapy
Authors: Tzu-Yun Kuo, Aisha Hasan, Richard J O'Reilly
Journal: Blood (2014)
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.
Authors: Elena Zamagni, Nicoletta Testoni, Carolina Terragna, Paola Tacchetti, Chiara Nicci, Patrizia Tosi, Mauro Fiacchini, Francesca Patriarca, Francesco Di Raimondo, Lucio Catalano, Francesco Casulli, Silvestro Volpe, Luciano Masini, Antonio Ledda, Annamaria Brioli, Delia Cangini, Alessandro Gozzetti, Catello Califano, Claudia Cellini, Affra Carubelli, Alessandro Petrucci, Giuliana Leopardi, Lucia Pantani, Michela Ceccolini, Massimo Offidani, Giulia Perrone, Michele Baccarani, Michele Cavo
Journal: Blood (2009)
CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia
Authors: Mustafa Sevinc, Ahmet Emre Eskazan, Aydin Karabulut, Suzin Catal Tatonyan, Emine Gulturk, Ayse Salihoglu, Seniz Ongoren Aydin, M. Cem Ar, Zafer Baslar, A. Burhan Ferhanoglu, Nukhet Tuzuner, Yildiz Aydin, Ugur Ozbek, Teoman Soysal
Journal: Blood (2011)
FRI0407 Electrophysiological Cardiac Remodeling in Patients with Ankylosing Spondylitis
Authors: A. Nigmatzyanova, M. Mangusheva, S. Lapshina, D. Abdulganieva, M. Afanasieva, L. Myasoutova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The question of the defeat of the cardiovascular system in patients with ankylosing spondylitis (AS) is very actual <h3>Objectives</h3> To study early pre-clinical parameters of myocardial electric instability and changing the geometry of the myocardium of the left ventricle (LV) in patients with AS and their relationship to the course of the disease. <h3>Methods</h3> 30 patients (22 men and 8 women) aged 21 to 56 years (mean 40,3±10,0 years) with significant AS without clinical manifestations of cardiovascular pathology at the time of inspection, in a disease history and/or according to medical records were observed. The duration of AS symptoms at the time of examination was less than 5 years – 15 patients (50%), from 5–10 years – in 5 (16.6%), more than 10 years – in 10 (33.4%) patients. Disease activity (BASDAI) was low in 6 (20%), moderate – in 9 (30%), high – in 7 (23.3%), very high – in 8 (26.7%) patients, the mean BASDAI 5 06 ± 1,4. Echocardioscopy with determination of left ventricular hypertrophy (LVH) according to recommendations of the ASE and EAE (2005/2006) was used to estimate the heart. geometry. The direction of maximum QRS vector to the left and back, the excess of 2.0 mV on the horizontal plane, and 2.2 mV on the frontal plane were assessed by vectorcardiography <h3>Results</h3> According to echocardioscopy in 9 (30%) patients with AS revealed changes in the geometry of the heart were found: concentric remodeling – in 2 (22.2%), eccentric hypertrophy – in 4 (44.5%), concentric hypertrophy – 3 (33.3%) patients. Vectorcardiography showed changes in the QRS loop in 4 (13.3%) patients. Also, a change in direction of the maximum vector during normal QRS loop area was revealed, which is associated with an increase in the size of the left ventricular chambers. Changes of the heart geometry were different depending on the AS activity: moderate activity concentric remodeling occurred in 2 (22.2%) patients, high activity–concentric hypertrophy in 3 (33.3%) patients, very high activity–eccentric hypertrophy in 4 (44.5%) (p≤0.05). The change in QRS loop was in 1 (3.3%) patient with low activity, and in 2 (6.6%) patients with high and very high disease activity. The concentric remodeling was found in 2 (22.2%) patients, concentric hypertrophy – in 3 (33.3%) patients with disease duration from 5 to 10 years; more than 10 years – eccentric hypertrophy in 4 (44.5%) patients. <h3>Conclusions</h3> The high frequency of preclinical changes in the geometry of myocardium in AS was assessed, more frequent in patients with high activity and disease duration less than 10 years. According to echocardioscopy, electrophysiological abnormalities in the myocardium were found in patients with saved geometry <h3>Disclosure of Interest</h3> None declared
Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants
Authors: V Pastor, S Hirabayashi, A Karow, J Wehrle, E J Kozyra, R Nienhold, G Ruzaike, D Lebrecht, A Yoshimi, M Niewisch, T Ripperger, G Göhring, I Baumann, S Schwarz, B Strahm, C Flotho, R C Skoda, C M Niemeyer, M W Wlodarski
Journal: Leukemia (2016)
Recovery Of Gamma/Delta+ T Cells After Transplantation With Alpha-Beta+/CD19+ Lymphocyte Depleted Hematopoietic Stem Cells From HLA-Haploidentical Donors
Authors: Irma Airoldi, Ignazia Prigione, Alice Bertaina, Claudia Cocco, Daria Pagliara, Alessia Zorzoli, Sergio Rutella, Rita M Pinto, Vito Pistoia, Riccardo Masetti, Mariateresa Romano, Francesca Di Florio, Francesca Del Bufalo, Lorenzo Moretta, Franco Locatelli
Journal: Blood (2013)
PTU-120 Extended Bravo Studies (>48 HRS) Improves Diagnostic Yield of Gastro-Oesophageal Reflux Disease (GORD) In Patients with Normal Multichannel Intraluminal Impedance-PH (MII-PH) Studies
Authors: C Chia, I Miah, I Koumoutsos, I Nasr, T Wong
Journal: Gut (2016)

<h3>Introduction</h3> MII-pH catheter studies measure both acid and non-acid reflux and are considered by some to be the gold standard in the diagnosis of GORD. Wireless pH capsule (Bravo) may increase the diagnostic yield of standard 24 hr catheter-based studies by overcoming the limitation of day-to-day reflux variability. This study aims to assess the additional diagnostic yield of extended Bravo recordings (up to 96 hours) in patients with normal 24 hr MII-pH results. <h3>Methods</h3> A total of 44 patients with typical GORD symptoms but negative 24 hr MII-pH studies off proton pump inhibitor(PPI) were referred for Bravo capsule studies. Bravo studies were performed beyond 48 hrs (up to 96 hrs). Bravo analysis was conducted using the ‘Worst Day Analysis’ (WDA) and ‘Average Day Analysis’ (ADA). Reference values for MII-pH and Bravo equivalent were adopted from internationally established studies (Table 1). Subgroup analyses were made on cohorts whose MII-pH showed normal AET with (A) normal number of total reflux events (TRE), (B) normal number of non-acid reflux (NAR) events and (C) increased number of NAR events. Statistical analysis was performed using SPSS V20. <h3>Results</h3> Our study group (male = 14, female =30) successfully completed Bravo studies up to 96 hours in 77.3% and beyond 48 hours in 97.7%. Using the WDA and ADA respectively, Bravo (AET cut-off &gt;4.2%) captured an additional 59.1% and 43.2% of patients with increased AET (p &lt; 0.001) in cases with normal AET on MII-pH. In MII-pH subgroups (A), (B) and (C), Bravo WDA was able to reveal an additional positive AET of 61.8%(p &lt; 0.001), 60.9%(p &lt; 0.001) and 50.0%(p = 0.016) respectively compared to MII-pH. Inclusion of symptom reflux association in Bravo cases with increased AET also showed additional diagnostic yield over MII-pH ranging from 42.9–47.7% (p ≤ 0.031) across all subgroups. <h3>Conclusion</h3> Extended Bravo studies (&gt;48hours) diagnosed GORD in more than half of cases with an initial normal MII-pH. Half of those with increased NAR events on MII-pH showed positive acid reflux on prolonged Bravo. This additional yield can alter diagnosis from functional heartburn/hypersensitive oesophagus to GORD in difficult cases and influence management. <h3>Disclosure of Interest</h3> None Declared
AB0384 The Effects of Pentoxifylline on Rheumatoid Arthritis Activity According To The DAS28 CRP Disease Activity Score:
Authors: D.S. Bublikov, A.V. Andrienko, V.G. Lychev, D.A. Anchugina
Journal: Annals of the Rheumatic Diseases (2016)

Background  Treatment of rheumatoid arthritis (RA) prior to “Treat to target” is difficult enough, forcing researchers around the world look for ways to improve the effectiveness of RA treatment.  Objectives  To explore the possibilities of reducing RA activity on the disease activity score DAS28 CRP by adding pentoxifylline to the methotrexate treatment.  Methods  This study included women (n=101) with RA longer than 1 year in duration, have a seropositive rheumatoid factor, and DAS28 CRP activity score of 3.2–5.1. Middle aged – 45.04±5.24 years old. All patients received a 15.50±2.50 mg oral dose of methotrexate per week. Patients were divided into two groups - those who only had methotrexate (n=50) and those who were treated with an oral dose of methotrexate and 1200 mg of pentoxifylline per day (n=51).  Results  The baseline for both groups of RA patients did not differ significantly in terms of the level on the DAS28 CRP (p=0.812). On 14th day of the group who were taking pentoxifylline, the DAS28 CRP disease activity score was significantly lower by 12.5% (p  The disease activity index for the two groups for 14 and 28 days is shown in the table.  Conclusions  Thus, converting the monotherapy methotrexate to pentoxifylline will significantly reduce the activity of RA, while avoiding many of the adverse effects of the other combination therapies. This data requires further long-term research.  Disclosure of Interest  None declared
Metabolites of Tryptophan Catabolism Are Elevated in Sera of Patients with Myelodysplastic Syndromes and Inhibit Hematopoietic Progenitor Amplification
Authors: Céline Berthon, Michaela Fontenay, Selim Corm, Isabelle Briche, Michel Lhermitte, Bruno Quesnel
Journal: Blood (2012)
Real-Time Quantitative Y Chromosome Specific PCR vs. XY-FISH vs. Fluorescent STR-PCR for Chimerism Analysis after Allogeneic Sex-Mismatched PBSCT.
Authors: Ulrike Baak, Olga Marinets, Kathrin Rieger, Igor Wolfgang Blau, Lutz Uharek, Thomas Burmeister, Eckhard Thiel
Journal: Blood (2004)
SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987)
Authors: Eileen P. Smith, Hongli Li, Jonathan W. Friedberg, Louis Constine, Lisa M. Rimsza, Ginna G. Laport, Leslie L. Popplewell, David G Maloney, Michael Leblanc, Stephen J. Forman, Richard I. Fisher, Patrick J. Stiff
Journal: Blood (2014)
International Development of An EORTC Measure to Assess Patient-Reported Quality of Life (QoL) and Symptoms in Chronic Myeloid Leukemia (CML)
Authors: Fabio Efficace, Massimo Breccia, Susanne Saussele, Ute Kossak, Giovanni Caocci, Mirjam Sprangers, Weichu Chie, Adel Naeem, Ourania Nicolatou-Galitis, Marco Vignetti, Annarita Cardoni, Franco Mandelli, Michele Baccarani
Journal: Blood (2011)